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Mounting evidence indicates that human neoplasms 
are dynamic, heterogeneous and hierarchical systems 
maintained by subpopulations of immature, self-
renewable and multipotent cells known as cancer stem 
cells (CSCs). CSCs are considered (1) drivers of tumor 
initiation, progression and spreading; (2) promoters of 
chemotherapeutic resistance; and (3) seeds for tumor 
relapse [1]. Further underscoring the relevance of CSCs 
in tumor pathology, (cancer) stemness gene signatures 
have been correlated with poor clinical outcomes [2]. The 
eradication of CSCs is thus required for an efficient cancer 
therapy.
Very recently, we performed a study to identify 
novel anti-CSC compounds to be clinically investigated 
as standalone agents [3]. For this, we took advantage 
of a large panel of multicellular spheroids enriched for 
CSCs that were derived from colorectal cancer (CRC) 
patient specimens. These tumorspheres, to which we will 
hereafter refer to as CRC-SCs, were all characterized at 
genetic and cytogenetic levels [3]. A drug library high-
throughput screening on three selected CRC-SCs led to the 
identification of LY2606368 - a novel checkpoint kinase 1 
(CHEK1, best known as CHK1) and CHK2 inhibitor also 
known as prexasertib [4] - as one potent CRC-SC killing 
agent [3]. When we extended the analysis to the panel of 
CSCs, we observed a heterogeneous response, with three 
groups of LY2606368 sensitivity: high sensitive, medium 
sensitive and low sensitive/resistant CRC-SCs. We were 
also able to demonstrate that LY2606368 preferentially 
depleted the CSC fraction exclusively in responsive (i.e., 
high or medium sensitive) CRC-SCs. CSC eradication by 
LY2606368 occurred (1) in vitro, as shown by the decrease 
in the percentage of cells positive for the colorectal CSC 
markers CD44v6 and ephrin B2 (EFNB2) or displaying 
high level of WNT activity; and (2) in vivo, as proven by 
the diminished tumor growth potential of LY2606368-
treated primary and secondary xenografts derived from 
CRC-SCs [3].
We then elucidated the mechanisms of CSC killing 
by LY2606368, showing that it involved the inhibition of 
CHK1 activity followed by a lethal increase in the levels 
of replication stress (RS). In more detail, CHK1 inhibition 
by LY2606368 simultaneously impaired the DNA 
replication process and the intra-S checkpoint resulting in 
DNA damage accrual, premature mitoses and cell death 
[3].
Next, we performed a protein network analysis 
by reverse-phase protein microarrays (RPPA) finding 
that LY2606368-responding CRC-SCs presented signs 
of ongoing RS response, including the phosphorylation 
of ATM serine/threonine kinase (ATM) and replication 
protein A2 (RPA2, best known as RPA32), coupled 
to high basal levels of endogenous DNA damage. 
Immunohistochemistry analyses on sections from CSC-
derived xenografts further confirmed DNA damage 
response (DDR) overactivation and high RS levels at 
baseline as biomarkers of the response to LY2606368. By 
combining genetic and cytogenetic profiles with sensitivity 
data we also found an association between LY2606368 
sensitivity and either mutation(s) of the tumor protein p53 
(TP53, best known as p53) or increased chromosomal 
content (i.e., hyperdiploidy). Accordingly, the constitutive 
depletion of p53 or the pharmacological induction of 
whole-genome redoubling sensitized previously resistant 
CRC-SCs to LY2606368 [3].
To sum up, our results indicate that RS in CRC-SCs 
is promoted by (1) the abrogation of p53 functions, which 
leads to diminished DNA repair efficiency, unscheduled 
S-phase entry and/or tolerance to (and protection from 
cell death induced by) RS; and (2) hyperdiploidy, which 
increases the risks to incorrectly duplicate the DNA. 
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Figure 1: Depleting CRC-SCs by CHK1 inhibition. 
A. High levels of replication stress (RS) due to TP53 mutation 
(nuclei contoured in red) and/or hyperdiploidy (increased nuclear 
size) render CRC-SCs targetable with CHK1 inhibitors. B. 
Strategies aimed at boosting RS, increasing ploidy, or abrogating 
the p53 pathway can sensitize previously resistant CRC-SCs to 
the inhibition of CHK1.
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Of note, high levels of RS make CRC-SCs particularly 
dependent on the activity of the RS response player CHK1 
(Figure 1). 
CSCs are reported to share with embryonic and 
adult SCs a very robust DDR as a means to counter DNA 
lesions arising from endogenous and exogenous sources 
[5]. Beyond constituting a barrier to tumorigenesis, 
the DDR appears indispensable for the survival and 
fitness of established, genomically-instable tumors 
thereby representing a candidate anti-cancer target [6, 
7]. In our study, we added a further layer of complexity 
showing that only a subset of CSCs (i.e., those bearing 
TP53 mutation(s) and elevated chromosomal content) 
displayed high basal levels of endogenous DNA damage, 
which conferred them a peculiar dependency on CHK1 
functions. Importantly, our results can pave the way to the 
entry of CHK1 inhibitors into the clinical practice for the 
eradication of colorectal tumors presenting replication-
stressed, p53-deficient and hyperdiploid CSCs.
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